Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-08
2009-06-16
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S268100, C546S269700, C546S270700
Reexamination Certificate
active
07547711
ABSTRACT:
The present invention provides compounds of formula Iand pharmaceutically acceptable salts thereof.The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
REFERENCES:
patent: 6040321 (2000-03-01), Kim et al.
patent: 6214852 (2001-04-01), Kim et al.
patent: 6262096 (2001-07-01), Kim et al.
patent: 6515004 (2003-02-01), Misra et al.
patent: 6670357 (2003-12-01), Leftheris et al.
patent: 6867300 (2005-03-01), Godfrey, Jr. et al.
patent: 6869952 (2005-03-01), Bhide et al.
patent: 6908916 (2005-06-01), Mastalerz et al.
patent: 6951859 (2005-10-01), Bhide et al.
patent: 6962915 (2005-11-01), Das et al.
patent: 6982265 (2006-01-01), Hunt et al.
patent: 7084160 (2006-08-01), Borzilleri et al.
patent: 2003/0232831 (2003-12-01), Dyckman et al.
patent: 2004/0082582 (2004-04-01), Dyckman et al.
patent: WO 99/65884 (1999-12-01), None
Kim et al (2001): STN International CAPLUS database, Columbus (Ohio), Accession No. 2001:521913.
Ferrand, G. et al., Synthese et proprietes pharmacologiques de derives aminothiazoliques:, Eur. J. Med. Chem., vol. 10, No. 6, pp. 549-556 (1975).
Fan et al., Trend Pharcol. Sci., vol. 16, pp. 57-66 (1995).
Folkman, Nature Medicine, vol. 1, pp. 27-31 (1995).
Cullinan-Bove et al., Endocrinology, vol. 133, pp. 829-837 (1993).
Senger et al., Cancer and Metastasis Reviews, vol. 12, pp. 303-324 (1993).
DeVries et al., Science, vol. 255, pp. 989-991 (1992).
Terman et al., Biochem. Biophys. Res. Comm., vol. 187, pp. 1579-1586 (1992).
Jakeman et al., Endocrinology, vol. 133, pp. 848-859 (1993).
Kolch et al., Breast Cancer Research and Treatment, vol. 36, pp. 139-155 (1995).
Connolly et al., J. Biol. Chem., vol. 264, pp. 20017-20024 (1989).
Kim et al. (2001): STN International CAPLUS database, Columbus (Ohio), Accession No. 2001:521913.
Bhide Rajeev S.
Borzilleri Robert M.
Cai Zhen-Wei
Qian Ligang
Tokarski John S.
Bristol--Myers Squibb Company
Korsen Elliott
Shameem Golam M
LandOfFree
Heterocyclic inhibitors of kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic inhibitors of kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic inhibitors of kinases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4090640